Dynavax Technologies (NASDAQ:DVAX) Posts Earnings Results, Meets Estimates

Dynavax Technologies (NASDAQ:DVAX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05, Zacks reports. Dynavax Technologies had a net margin of 7.85% and a return on equity of 3.19%. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million.

Dynavax Technologies Trading Up 2.6 %

Shares of Dynavax Technologies stock traded up $0.35 on Friday, hitting $13.68. 984,972 shares of the company traded hands, compared to its average volume of 1,779,353. The stock’s 50 day moving average price is $12.81 and its 200-day moving average price is $11.99. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.05. The company has a market cap of $1.80 billion, a PE ratio of 105.20 and a beta of 1.32.

Analysts Set New Price Targets

A number of research analysts recently commented on DVAX shares. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.